Holen Sie sich die Stockscreener-App
3.64
16.67%
0.52
Handel nachbörslich:
3.67
0.03
+0.82%
Schlusskurs vom Vortag:
$3.12
Offen:
$3.04
24-Stunden-Volumen:
1.31M
Relative Volume:
0.33
Marktkapitalisierung:
$41.53M
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-101.98M
KGV:
-0.3788
EPS:
-9.6101
Netto-Cashflow:
$-112.43M
1W Leistung:
-11.65%
1M Leistung:
+130.38%
6M Leistung:
-66.83%
1J Leistung:
-82.26%
1-Tages-Spanne:
$3.0235
$3.79
1-Wochen-Bereich:
$3.0235
$4.09
52-Wochen-Spanne:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Firmenname
X 4 Pharmaceuticals Inc
Sektor
Branche
Telefon
857-529-8300
Adresse
61 NORTH BEACON STREET, BOSTON, MA
Vergleichen Sie XFOR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.64 | 77.90M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-12 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-12-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Eingeleitet | Piper Sandler | Overweight |
| 2019-12-23 | Eingeleitet | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | ROTH Capital | Buy |
| 2019-12-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-12-05 | Eingeleitet | B. Riley FBR | Buy |
| 2019-06-07 | Eingeleitet | Stifel | Buy |
| 2019-06-05 | Eingeleitet | Cowen | Outperform |
Alle ansehen
X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten
Is X4 Pharmaceuticals Inc. stock a value trapJuly 2025 Macro Moves & Breakout Confirmation Alerts - khodrobank.com
Is X4 Pharmaceuticals Inc. forming a breakout patternJuly 2025 Macro Moves & AI Powered Market Entry Strategies - khodrobank.com
X4 Pharmaceuticals Inc. stock trendline breakdownMarket Volume Summary & AI Enhanced Trading Signals - Newser
Using R and stats models for X4 Pharmaceuticals Inc. forecasting2025 Earnings Surprises & AI Driven Price Predictions - Newser
Applying chart zones and confluence areas to X4 Pharmaceuticals Inc.July 2025 Review & Entry Point Confirmation Signals - Newser
What to expect from X4 Pharmaceuticals Inc. in the next 30 daysOptions Play & Real-Time Market Sentiment Alerts - Newser
X4 Pharmaceuticals Inc. stock outlook for YEARPortfolio Return Summary & Verified Momentum Stock Watchlist - Newser
How to recover losses in X4 Pharmaceuticals Inc. stockInsider Buying & Step-by-Step Swing Trade Plans - Newser
Is X4 Pharmaceuticals Inc. trending in predictive chart modelsShort Setup & Advanced Technical Analysis Signals - Newser
Is X4 Pharmaceuticals Inc. a top pick in the sectorWeekly Trade Summary & AI Driven Stock Movement Reports - khodrobank.com
Is X4 Pharmaceuticals Inc. stock ready for a breakout2025 Market Outlook & Fast Exit and Entry Strategy Plans - Newser
X4 Pharmaceuticals Inc. stock prediction for this weekTrade Entry Report & Fast Entry High Yield Stock Tips - Newser
X4 Pharmaceuticals Inc. stock trend forecastQuarterly Portfolio Review & Safe Swing Trade Setups - Newser
Intraday pattern recognizer results for X4 Pharmaceuticals Inc.2025 Volume Leaders & Free High Return Stock Watch Alerts - Newser
How to use a screener to detect X4 Pharmaceuticals Inc. breakoutsQuarterly Performance Summary & Consistent Return Investment Signals - Newser
What’s the beta of X4 Pharmaceuticals Inc. stockMarket Sentiment Report & AI Powered Buy/Sell Recommendations - khodrobank.com
Is X4 Pharmaceuticals Inc. stock entering bullish territoryDividend Hike & Smart Allocation Stock Reports - Newser
What is the target price for X4 Pharmaceuticals Inc. stockRate Cut & AI Enhanced Market Trend Forecasts - khodrobank.com
Identifying reversal signals in X4 Pharmaceuticals Inc.July 2025 Reactions & Low Risk Entry Point Guides - Newser
Is X4 Pharmaceuticals Inc. forming a reversal patternMarket Sentiment Summary & High Conviction Buy Zone Picks - Newser
Price momentum metrics for X4 Pharmaceuticals Inc. explainedMarket Growth Summary & Fast Gain Swing Trade Alerts - Newser
Trend analysis for X4 Pharmaceuticals Inc. this weekQuarterly Portfolio Report & AI Forecast for Swing Trade Picks - Newser
X4 Pharmaceuticals Inc. stock daily chart insightsInsider Buying & Daily Stock Trend Watchlist - Newser
Is X4 Pharmaceuticals Inc. stock influenced by commodity prices2025 Market Overview & AI Driven Price Predictions - خودرو بانک
Multi asset correlation models including X4 Pharmaceuticals Inc.Long Setup & Real-Time Chart Breakout Alerts - Newser
Real time breakdown of X4 Pharmaceuticals Inc. stock performanceMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
What Fibonacci levels say about X4 Pharmaceuticals Inc. reboundJuly 2025 Update & Trade Opportunity Analysis - Newser
Will X4 Pharmaceuticals Inc. continue its uptrend2025 Top Decliners & AI Driven Stock Reports - Newser
Published on: 2025-08-31 02:01:17 - Newser
Stifel Nicolaus Issues Pessimistic Forecast for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price - Defense World
Will X4 Pharmaceuticals Inc. outperform the market2025 Year in Review & Verified Chart Pattern Signals - Newser
Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)
Umsatz
Nettogewinn
Free Cashflow
ENV
X 4 Pharmaceuticals Inc-Aktie (XFOR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baldry Mark | Chief Commercial Officer |
Nov 15 '24 |
Buy |
0.34 |
13,404 |
4,598 |
129,173 |
| Ragan Paula | President and CEO |
Jan 24 '25 |
Sale |
0.45 |
76,473 |
34,719 |
1,087,386 |
| Mostafa Adam S. | Chief Financial Officer |
Jan 24 '25 |
Sale |
0.45 |
74,773 |
33,947 |
0 |
| Baldry Mark | Chief Commercial Officer |
Jan 24 '25 |
Sale |
0.45 |
29,159 |
13,241 |
94,123 |
| DiBiase Mary | Chief Operating Officer |
Jan 24 '25 |
Sale |
0.45 |
22,258 |
10,094 |
490,980 |
| Arbet-Engels Christophe | Chief Medical Officer |
Jan 24 '25 |
Sale |
0.45 |
11,624 |
5,284 |
14,207 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):